LIEBREGTS, Max, Lothar FABER, Morten K. JENSEN, Pieter A. VRIESENDORP, Jaroslav JANUSKA, Jan KREJČÍ, Peter R. HANSEN, Hubert SEGGEWISS, Dieter HORSTKOTTE, Radka ADLOVA, Henning BUNDGAARD, Jurriën M. ten BERG a Josef VESELKA. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy. JACC - Cardiovascular Interventions. New York: Elsevier Science Inc., roč. 10, č. 11, s. 1135-1143. ISSN 1936-8798. doi:10.1016/j.jcin.2017.03.030. 2017.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy
Autoři LIEBREGTS, Max (528 Nizozemské království), Lothar FABER (276 Německo), Morten K. JENSEN (208 Dánsko), Pieter A. VRIESENDORP (528 Nizozemské království), Jaroslav JANUSKA (203 Česká republika), Jan KREJČÍ (203 Česká republika, garant, domácí), Peter R. HANSEN (208 Dánsko), Hubert SEGGEWISS (276 Německo), Dieter HORSTKOTTE (276 Německo), Radka ADLOVA (203 Česká republika), Henning BUNDGAARD (208 Dánsko), Jurriën M. ten BERG (528 Nizozemské království) a Josef VESELKA (203 Česká republika).
Vydání JACC - Cardiovascular Interventions, New York, Elsevier Science Inc. 2017, 1936-8798.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 9.881
Kód RIV RIV/00216224:14110/17:00097296
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.jcin.2017.03.030
UT WoS 000402974900013
Klíčová slova anglicky alcohol septal ablation; hypertrophic cardiomyopathy; septal reduction therapy
Štítky EL OK
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Soňa Böhmová, učo 232884. Změněno: 20. 3. 2018 16:15.
Anotace
OBJECTIVES The aim of this study was to describe the safety and outcomes of alcohol septal ablation (ASA) in younger patients with obstructive hypertrophic cardiomyopathy. BACKGROUND The American College of Cardiology Foundation/American Heart Association guidelines reserve ASA for older patients and patients with serious comorbidities. Data on long-term age-specific outcomes after ASA are scarce. METHODS A total of 1,197 patients (mean age 58 +/- 14 years) underwent ASA for obstructive hypertrophic cardiomyopathy. Patients were divided into young (<= 50 years), middle-age (51 to 64 years), and older (>= 65 years) groups. RESULTS Thirty-day mortality and pacemaker implantation rates were lower in young compared with older patients (0.3% vs. 2%[p = 0.03] and 8% vs. 16%[p < 0.001], respectively). Ninety-five percent of young patients were in New York Heart Association functional class I or II at last follow-up. During a mean follow-up period of 5.4 +/- 4.2 years, 165 patients (14%) died. Annual mortality rates of young, middle-age, and older patients were 1%, 2%, and 5%, respectively (p < 0.01). Annual adverse arrhythmic event rates were similar in the 3 age groups at about 1%(p = 0.90). Independent predictors of mortality in young patients were age, female sex, and residual left ventricular outflow tract gradient. Additionally, young patients treated with >= 2.5 ml alcohol had a higher all-cause mortality rate (0.6% vs. 1.4% per year in patients treated with < 2.5 ml, p = 0.03). CONCLUSIONS ASA in younger patients with obstructive hypertrophic cardiomyopathy was safe and effective for relief of symptoms at long-term follow-up. The authors propose that the indication for ASA can be broadened to younger patients. (J Am Coll Cardiol Intv 2017;10:1134-43) (C) 2017 by the American College of Cardiology Foundation.
VytisknoutZobrazeno: 28. 3. 2024 19:03